
Tirzepatide appears more cost-effective than semaglutide for obesity and knee osteoarthritis, though long-term data and patient-centered outcomes remain key.
Elena Losina, PhD is the codirector of the Orthopedics and Arthritis Center for Outcomes Research at Brigham and Women’s Hospital
Tirzepatide appears more cost-effective than semaglutide for obesity and knee osteoarthritis, though long-term data and patient-centered outcomes remain key.
Tirzepatide’s cost-effectiveness provides key evidence for policy makers implementing clinical coverage decisions.
Elena Losina, PhD, codirector of the Orthopedics and Arthritis Center for Outcomes Research at Brigham and Women’s Hospital, discusses the cost-effectiveness of varying weight loss interventions.
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.